Diseases of the Respiratory Tract: Asthma and Chronic Obstructive Pulmonary Disease  

作　　者：Sara M Tony Mohamed EA Abdelrahim 

机构地区：[1]Beni-Suef Specialized Hospital,Beni-Sueft Egypt [2]Clinical Pharmacy Department,Faculty of Pharmacy,Beni-Suef University Beni-Suef,Egypt

出　　处：《Journal of Clinical and Nursing Research》2022年第3期236-250,共15页临床护理研究（英文）

摘　　要：Short acting β2-agonists(SABAs)such as salbutamol and terbutaline are commonly used in the treatment of asthma and chronic obstructive pulmonary disease(COPD).According to the guideline produced by the British Thoracic Society(BTS)and the Scottish Intercollegiate Guidelines Network(SIGN),SABAs are considered to be the first line of treatment in asthma management.The National Institute for Health and Clinical Excellence(NICE)guidelines also recommend the use of SABA as the first line of treatment for managing patients with COPD.The recommendations in NICE guidelines state that in COPD patients,breathlessness and exercise limitation should be first medicated with short-acting bronchodilators(including β2-agonists or anticholinergics)when it is required.Both salbutamol and terbutaline have been widely used for asthma and COPD,and they have been found to be extremely beneficial in the two pathologic conditions.

关 键 词：Respiratory tract ASTHMA COPD 

分 类 号：R56[医药卫生—呼吸系统]